FOLH1 and renal carcinoma: This variable expression makes PSMA a potential molecular target for diagnosis and therapy in other malignancies such as breast cancer [196, 197], colorectal cancer [198, 199], renal cancer [200, 201], glioblastoma multiform [202, 203], thyroid cancer [204, 205], pancreatic cancer [206], hepatocellular cancer [207] and others [195, 208, 209].